CV Sciences, Inc. (CVSI) Form 8-K — Aug 13, 2026
CV Sciences reported second quarter 2026 revenue of $3.0 million, down 17.5% from $3.6 million in the year-ago quarter, with the GAAP net loss widening to $775,000 from $261,000. The company cut operating expenses 11.3% year over year to $1.7 million and generated $121,000 of operating cash flow in the first half, but adjusted EBITDA swung to a $0.1 million loss and cash ended the quarter at just $0.3 million. Management attributed the sales decline to restrictive federal and state regulations on hemp-derived cannabinoids, while highlighting a 61-32 U.S. Senate vote approving H.R.
Key figures
- Eps
- -0.00 (Q2 2026 GAAP, basic and diluted); -0.01 (six months 2026 GAAP)
- Revenue
- 2985000
- Revenue Yoy
- -17.5%
- Total Assets
- 6521000
- Cash Position
- 266000
- Shares Outstanding
- 213,122 thousand shares (213.1 million) as of June 30, 2026, up from 184,264 thousand at December 31, 2025
- Opex Reduction Yoy
- -11.3%
- Gross Margin Q2 2025
- 50.9%
- Gross Margin Q2 2026
- 48.6%
- Unit Sales Change Yoy
- -14.9%
- Adjusted Ebitda Q2 2025
- 59000
- Loss On Debt Conversion Q2
- 104000
- New Product Revenue Share
- 44% of Q2 2026 net revenue from products launched since January 1, 2023
- Operating Expenses Q2 2026
- 1751000
- Operating Cash Flow Six Months
- 121000
- Convertible Notes At Fair Value
- 1017000
- Change In Fair Value Convertible Notes Q2
- 364000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.